Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis B Vaccine for Maintenance of Clinical Recovery in CHB
NCT06803368Recruiting
- Sponsor
- Beijing Hospital Authority
- Start
- Nov 2024
- Primary completion
- Oct 2027
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Randomised, open-label trial of Hepatitis B vaccine in Chronic Hepatitis B (CHB) (3 arms), sponsored by Beijing Hospital Authority. Primary endpoints: Sustained response rate by virological and serological indicators and Relapse rate by virological and serological indicators. Started Nov 2024; status: recruiting.
02
Drugs
Hepatitis B vaccine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06803368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803368.